You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
格隆汇港股聚焦(9.03)︱中国恒大前8月合约销售4506亿元;信达生物阿达木单抗正式获批上市
格隆汇 09-03 23:14

【运营数据】

中国恒大(03333.HK)前8月合约销售4506.2亿元 同比增长21.8%

融信中国(03301.HK)8月总合约销售额120.31亿元 同比增长10.09%

越秀地产(00123.HK)8月合同销售76.57亿元 同比上升约132%

雅居乐集团(03383.HK):8月预售金额119.6亿元 同比增长17.8%

银城国际控股(01902.HK)8月份合约销售同比增长86.97%

首创置业(02868.HK):8月签约额38.5亿元 同比增长30.5%

德信中国(02019.HK)8月合约销售额67.4亿元 同比增长81.18%

大发地产(06111.HK)前8个月销售额达160.02亿元

捷利交易宝(08017.HK)8月注册用户量同比增长58.2%

【增减持】

香港建设(控股)(00190.HK)斥1.25亿港元收购604万股小米集团(01810.HK)股份

青岛啤酒股份(00168.HK):复星集团减持公司3600万股H股

睿见教育(06068.HK)控股股东刘学斌再次增持100万股

【股权变更】

山东国信(01697.HK):山东高新投拟将所持公司4.83%股权转让予鲁信集团

【股本重组】

艾硕控股(08341.HK)拟“1供3”供股 筹集最多4800万港元

【并购出售】

正乾金融控股(01152.HK)拟85万元收购深圳综合跨境电商平台

【重大事项】

创维集团(00751.HK)股份回购要约截止 黄氏一致行动集团持股将增至46.90%

励晶太平洋(00575.HK):Fortacin营销授权由处方药转为非处方药以大幅提升销量

李氏大药厂(00950.HK)抗精神病吸入剂产品研究达到主要终点指标

信达生物(01801.HK):苏立信®(阿达木单抗生物类似药)获批上市

康宁杰瑞制药-B(09966.HK)治疗胸腺上皮肿瘤新药获孤儿药资格认定

中国同辐(01763.HK)附属与韩国FC于放射性FC303药物开发和商业化进行合作

【公司改名】

中粮肉食(01610.HK)拟更名为“中粮家佳康食品”

【回购注销】

中国旺旺(00151.HK)9月3日耗资5945.46万港元回购1100万股

合生创展集团(00754.HK)9月3日耗资1498.59万港元回购95万股

复星国际(00656.HK)9月3日耗资1722.8万港元回购200万股

石四药集团(02005.HK)9月3日耗资390.1万港元回购80万股

数码通电讯(00315.HK)9月3日耗资525.52万港元回购125万股

富智康集团(02038.HK)9月3日耗资182万港元回购200万股

金鹰商贸集团(03308.HK)9月3日耗资327.91万港元回购45.5万股

昊海生物科技(06826.HK)9月3日耗资101.06万港元回购1.77万股H股

DYNAM JAPAN(06889.HK)9月3日耗资307.35万港元回购38.94万股

康臣药业(01681.HK)9月3日耗资117.30万港元回购35.6万股

中国水务(00855.HK)9月3日耗资139.6万港元回购22.2万股

【股权激励】

高丰集团控股(02863.HK)授出4326万份购股权

金宝通(00320.HK)向执行董事黄华舜授出200万份购股权

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.
uSMART
Wealth Growth Made Easy
Open Account